Search for a clinical trial
Other search option(s)
276 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Terminated trial = 
; Funded by an IRDiRC member = 
; Member of a ERN = 
National clinical trial(s)
AUSTRIA
OBERÖSTERREICH
LINZ
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) - AT
Ordensklinikum Linz GmbH Barmherzige Schwestern
Interne I - Internistische Onkologie, Hämatologie u. Gastroenterologie
AUSTRIA
OBERÖSTERREICH
LINZ
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) - AT
Ordensklinikum Linz GmbH Elisabethinen
Interne 1 - Hämatologie mit Stammzelltransplantation, Hämostaseologie und medizinische Onkologie
AUSTRIA
SALZBURG
SALZBURG
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Innere Medizin III
AUSTRIA
TIROL
INNSBRUCK
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) - AT
Medizinische Universität Innsbruck
Universitätsklinik für Innere Medizin V - Hämatologie und Onkologie
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
POLO-AML-2: A phase III randomised, double-blind, controlled, parallel group study of intravenous Volasertib in combination with subcutaneous low-dose Cytarabine vs. placebo + low-dose Cytarabine in patients greater or equal to 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
MIRROS: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase III Study of Idasanutlin, an MDM2 Antagonist, With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
AMoRe2017: International multicenter, open-label, phase 2 study to treat molecular relapse of pediatric acute myeloid leukemia with Azacitidine - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Guadecitabine Clinical Studies (Phase 2) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase III, Randomized, Double-blind Study of Chemotherapy With Daunorubicin or Idarubicin and Cytarabine for Induction and Intermediate Dose Cytarabine for Consolidation Plus Midostaurin (PKC412) or Chemotherapy Plus Placebo in Newly Diagnosed Patients With FLT-3 Mutation Negative Acute Myeloid Leukemia (AML) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
BRIGHT AML1019: A randomized (1:1), double-blind, multi-center, placebo controlled study evaluating intensive chemotherapy with or without Glasdegib (PF-04449913) or Azacitidine with or without Glasdegib in patients with previously untreated acute myeloid leukemia (phase 3) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase II, open-label, single arm study to evaluate the safety, efficacy, and pharmacokinetics of twice daily midostaurin (PKC412) combined with standard chemotherapy and as a single agent post-consolidation therapy in children with untreated FLT3-mutated acute myeloid leukemia - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
HOVON 156 AML: A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
HOVON 150 AML: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy Followed by Maintenance Therapy in Patients With Newly Diagnosed AML or MDS With Excess Blasts-2, With an IDH1 or IDH2 Mutation [...] - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial (Phase 3) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase Ib study of Vyxeos® (liposomal daunorubicin and cytarabine) in combination with Clofarabine in children with relapsed/refractory AML - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A multi-center continuation study evaluating azacitidine with or without glasdegib (PF-04449913) in patients with previously untreated acute myeloid leukemia, myelodysplastic syndrome or chronic myelomonocytic leukemia (phase 3) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 1/2, Open-label, Multicenter Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia (AML) and Treatment-naïve Subjects With AML Who Are Not Eligible for Intensive Induction Chemotherapy - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
IDHENTIFY: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
AUSTRIA
WIEN
WIEN
A Phase 1/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
AUSTRIA
WIEN
WIEN
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) - AT
Hanusch Krankenhaus
3. Medizinische Abteilung (Hämatologie und Onkologie)
BELGIUM
ANTWERPEN
EDEGEM (ANTWERPEN)
WIDEA: Wilms' Tumor (WT1) Antigen-targeted Dendritic Cell Vaccination to Prevent Relapse in Adult Patients With Acute Myeloid Leukemia: a Multicenter Randomized Phase II Trial
Antwerp University Hospital - UZA
Antwerp University Hospital
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
ADMIRAL: A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation- BE
Institution: Information not provided - BE
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia - BE
Institution: Information not provided - BE
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy - BE
Cliniques universitaires Saint-Luc - UCLouvain
Department of Hematology
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
AMoRe2017: International multicenter, open-label, phase 2 study to treat molecular relapse of pediatric acute myeloid leukemia with Azacitidine - BE
Hôpital Universitaire des Enfants Reine Fabiola - HUDERF
Service d'hémato-oncologie, d'immunologie et de rhumatologie pédiatrique
BELGIUM
LIEGE
LIEGE
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1 (phase II)- BE
CHU de Liège - Site du Sart Tilman
Department of Hematology / Hématologie clinique - CHU de Liège
BELGIUM
OOST-VLAANDEREN
GENT
Étude de phase III randomisée et en double-aveugle portant sur l'administration d'une chimiothérapie d'induction (daunorubicine / cytarabine) et de consolidation (cytarabine à haute dose) + midostaurine (PKC412) (IND #101261) ou un placebo chez des patients âgés de moins de 60 ans et nouvellement diagnostiqués comme atteints d'une leucémie myéloïde aiguë (LMA) avec mutation du gène FLT3 - BE
Ghent University Hospital - UZ Gent
Dienst Hematologie
FINLAND
Finland
HELSINKI
Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens - FI
HUS - Helsinki University Hospital
Comprehensive Cancer Center
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
An open phase I/IIa trial to investigate the maximum tolerated dose, safety, pharmacokinetics and efficacy of intraveneous BI 6727 as monotherapy or in combination with subcutaneous cytarabine in patients with acute myeloid leukaemia - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
LYON
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission - FR
CLCC Léon Bérard
Centre Léon Bérard
FRANCE
ILE-DE-FRANCE
PARIS
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission - FR
GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis
Hôpital Saint Louis
FRANCE
ILE-DE-FRANCE
PARIS
A Phase 3 Open-label Randomized Study of Quizartinib AC220 Monotherapy Versus Salvage Chemotherapy in Subjects With Feline McDonough Sarcoma FMS Like Tyrosine Kinase 3 Internal Tandem Duplication FLT3 ITD Positive Acute Myeloid Leukemia AML Refractory to or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation HSCT Consolidation - FR
GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis
Service : Centre des Maladies du Sang
FRANCE
ILE-DE-FRANCE
PARIS
SAMBA-trial: Investigation of efficacy of the antibody JNJ-56022473 in MDS and AML patients, in which the treamtment with hypomethylating agents fails or the treatment with hypomethylating agents results in a relapse (Phase II) - FR
GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis
Service d'Hématologie seniors
FRANCE
OCCITANIE
TOULOUSE
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission - FR
IUCT Oncopole - CLCC Institut Claudius Regaud
Bureau des études cliniques
FRANCE
PAYS DE LA LOIRE
NANTES
FRANCE
PAYS DE LA LOIRE
NANTES
SET-RIC: Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Primary Treatment Failure - FR
CHU de Nantes - Hôtel Dieu
Service d'hématologie clinique
FRANCE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission - FR
CLCC Institut Paoli Calmettes
Institut Paoli-Calmettes
GERMANY
Baden-Württemberg
FREIBURG
AMLSG 14-09 (DECIDER): Prospective randomized multicenter phase II trial of low-dose Decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor Valproic Acid (VPA) and All-trans Retinoic Acid (ATRA) in patients > 60 years with Acute Myeloid Leukemia who are ineligible for induction chemotherapy
Universitätsklinikum Freiburg
Klinik für Innere Medizin I - Hämatologie, Onkologie und Stammzelltransplantation
GERMANY
Baden-Württemberg
FREIBURG
TRANSATRA: Phase I/II Study of Sensitization of Non-M3 Acute Myeloid Leukemia (AML) Blasts to All-trans Retinoic Acid (ATRA) by Epigenetic Treatment with Tranylcypromine (TCP), an Inhibitor of the Histone Lysine Demethylase 1 (LSD1) - DE
Universitätsklinikum Freiburg
Klinik für Innere Medizin I - Hämatologie, Onkologie und Stammzelltransplantation
GERMANY
Baden-Württemberg
FREIBURG
CA209-9P9: Phase 1/2 Study on the Efficacy of Nivolumab in the Recurrence of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
Universitätsklinikum Freiburg
Klinik für Innere Medizin I - Hämatologie, Onkologie und Stammzelltransplantation
GERMANY
Baden-Württemberg
FREIBURG
An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia - DE
Universitätsklinikum Freiburg
GERMANY
Baden-Württemberg
HEIDELBERG
BLAST: A double- blind, placebo controlled, randomized, multicenter, Phase II study to assess the efficacy of BL-8040 addition to consolidation therapy in AML patients - DE
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie
GERMANY
Baden-Württemberg
HEIDELBERG
An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia - DE
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie
GERMANY
Baden-Württemberg
ULM
GERMANY
Baden-Württemberg
ULM
Phase 1b Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia -DE-
Universitätsklinikum Ulm
GERMANY
Baden-Württemberg
ULM
An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia - DE
Universitätsklinikum Ulm
GERMANY
Baden-Württemberg
ULM
AMLSG 21-13: Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) - DE
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
GERMANY
Baden-Württemberg
ULM
SOPRA: A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) versus Specified Physician's Choice in Patients 60 Years and older with Relapsed/Refractory Acute Myeloid Leukemia (AML) Who are Ineligible for Intensive Chemotherapy and/or Transplantation - DE
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
GERMANY
Baden-Württemberg
ULM
A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy - DE
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
GERMANY
Baden-Württemberg
ULM
The IDHENTIFY Trial: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation - DE
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
GERMANY
Bayern
MÜNCHEN
An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia - DE
LMU Klinikum der Universität München - Campus Großhadern
LMU Klinikum
GERMANY
Bayern
MÜNCHEN
AARON: An Open-Label Phase II Study of Relatlimab (BMS-986016) With Nivolumab (BMS-936558) in Combination With 5-Azacytidine for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older Acute Myeloid Leukemia Patients
LMU Klinikum der Universität München - Campus Großhadern
Medizinische Klinik und Poliklinik III
GERMANY
Bayern
REGENSBURG
AMLSG 26-16 / AML-ViVA: Randomized Phase II trial with safety run-in phase evaluating low-dose azacitidine, all-trans retinoic acid and pioglitazone versus standard dose azacitidine in patients >=60 years with acute myeloid leukemia (AML) who are refractory to standard induction chemotherapy - DE
Universitätsklinikum Regensburg
Klinik und Poliklinik für Innere Medizin III
GERMANY
Bayern
REGENSBURG
CD-TCR-001: A Phase I/II, Open-Label, Non-Randomized, Multicentre, Dose-Escalation Clinical Trial with Control Group to Evaluate the Safety, Feasibility and Preliminary Efficacy of PRAME TCR Modified T Cells, MDG1011, in Subjects with High Risk Myeloid and Lymphoid Neoplasms
Universitätsklinikum Regensburg
Klinik und Poliklinik für Innere Medizin III
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation -DE-
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy -DE-
Institution: Information not provided - DE
GERMANY
Berlin
BERLIN
An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia - DE
Charité - Universitätsmedizin Berlin
GERMANY
Berlin
BERLIN
AMoRe2017: International multicenter, open-label, phase 2 study to treat molecular relapse of pediatric acute myeloid leukemia with Azacitidine -DE-
Otto-Heubner-Centrum für Kinder- und Jugendmedizin
Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie
GERMANY
Hamburg
HAMBURG
Phase 1b Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia -DE-
UKE - Universitätsklinikum Hamburg-Eppendorf
GERMANY
Hamburg
HAMBURG
An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia - DE
UKE - Universitätsklinikum Hamburg-Eppendorf
GERMANY
Hessen
FRANKFURT AM MAIN
An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia - DE
Universitätsklinikum Frankfurt
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
GERMANY
Hessen
FRANKFURT AM MAIN
TOR-AML: A double-blind, placebo-controlled, randomized, multicenter phase II trial to assess the efficacy of Temsirolimus added to standard primary therapy in elderly patients with newly diagnosed Acute Myeloid Leukemia (AML)
Universitätsklinikum Frankfurt
Universitäres Centrum für Tumorerkrankungen (UCT) Frankfurt
GERMANY
Hessen
FRANKFURT AM MAIN
A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) plus JNJ-56022473 (Anti-CD123) Versus DACOGEN (Decitabine) Alone in Patients with AML who are not Candidates for Intensive Chemotherapy - DE
Universitätsklinikum Frankfurt
Universitäres Centrum für Tumorerkrankungen (UCT) Frankfurt
GERMANY
Niedersachsen
BRAUNSCHWEIG
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase III Study of Idasanutlin, an MDM2 Antagonist, With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) - DE
Städtisches Klinikum Braunschweig - Standort Celler Straße
Klinik für Hämatologie und Onkologie
GERMANY
Niedersachsen
HANNOVER
ClAraC-SCT: Randomized, multicentre, phase II trial to compare the event-free survival of Clofarabine / Ara-C (ClAraC) or of FLAMSA treatment in patients with high risk AML or advanced MDS scheduled for allogeneic stem cell transplantation
Medizinische Hochschule Hannover
Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation
GERMANY
Niedersachsen
HANNOVER
An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia - DE
Medizinische Hochschule Hannover
Medizinische Hochschule Hannover (MHH)
GERMANY
Nordrhein-Westfalen
BONN
An International, Multicentre, Open-label Study To Evaluate The Efficacy and Safety of Two Different Vaccination Regimens of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia That Are In Remission With Persistent MRD -DE-
Universitätsklinikum Bonn (AöR)
Universitätsklinikum Bonn
GERMANY
Nordrhein-Westfalen
ESSEN
AML-BFM 2012: Clinical trial for the treatment of acute myeloid leukemia in children and adolescents
Universitätsklinikum Essen
Klinik für Kinderheilkunde III
GERMANY
Nordrhein-Westfalen
ESSEN
Clinical Phase III Trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic Stem Cell Transplantation in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) considered ineligible to standard conditioning regimens - DE
Universitätsklinikum Essen
Klinik für Knochenmarktransplantation
GERMANY
Nordrhein-Westfalen
MÜNSTER
PAZOPANIB-AML: Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible - DE
Universitätsklinikum Münster
Medizinische Klinik und Poliklinik A
GERMANY
Rheinland-Pfalz
MAINZ
GERMANY
Sachsen
DRESDEN
CALGB 10603: A Phase III randomized, double-blind study of induction (Daunorubicin/Cytarabine) and consolidation (High-Dose Cytarabine) chemotherapy + Midostaurin (PKC412) or Placebo in newly diagnosed patients < 60 years of age with FLT3 mutated Acute Myeloid Leukemia (AML)
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I
GERMANY
Sachsen
DRESDEN
MIDOKIT (TUD-MIDOKI-052): A single-arm phase II trial to assess the efficacy of Midostaurin (PKC412) added to standard primary therapy in patients with newly diagnosed c-KIT or FLT3-ITD mutated t(8;21) AML
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I
GERMANY
Sachsen
DRESDEN
DaunoDouble: Randomized comparison between two dose levels of Daunorubicin and between one versus two cycles of induction therapy for adult patients with Acute Myeloid Leukemia
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I
GERMANY
Sachsen
DRESDEN
A Multicenter, Open-label, Dose-escalating, Phase I Trial With GEM333, a CD33 Targeted Bispecific Antibody Engaging T-cells, in Relapsed or Refractory Acute Myeloid Leukemia - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I
GERMANY
Sachsen
DRESDEN
TUD-MOSAIC-075: MidOStaurin + Gemtuzumab OzogAmIcin Combination in First-line Standard Therapy for Acute Myeloid Leukemia
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I
GERMANY
Sachsen
DRESDEN
TUD-BRIDGE-046: Clofarabine salvage therapy in patients with relapsed or refractory Acute Myeloid Leukemia (Phase II Study)
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation
GERMANY
Sachsen
DRESDEN
ETAL3-ASAP: Evaluation of the Impact of Remission Induction Chemotherapy Prior to Allogeneic Stem Cell Transplantation in Relapsed and Poor-response Patients with AML (Phase III) - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation
GERMANY
Sachsen
DRESDEN
HINKL: Randomised controlled phase-2 trial to determine the efficacy of adoptive immunotherapy with haploidentical natural killer cells in high-risk acute myeloid leukemia - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Nationales Centrum für Tumorerkrankungen Dresden
GERMANY
Sachsen
DRESDEN
Phase 1b Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia -DE-
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden
GERMANY
Sachsen
DRESDEN
An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden
GERMANY
Sachsen
LEIPZIG
DELTA: A randomized placebo-controlled phase 2 study of decitabine/azacitidine with or without eltrombopag in AML patients = / > 65 years of age not eligible for intensive chemotherapy - DE
Universitätsklinikum Leipzig AöR
Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie
GERMANY
Sachsen
LEIPZIG
An International, Multicentre, Open-label Study To Evaluate The Efficacy and Safety of Two Different Vaccination Regimens of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia That Are In Remission With Persistent MRD -DE-
Universitätsklinikum Leipzig AöR
UCCL - Universitäres Krebszentrum Leipzig
GERMANY
Sachsen
LEIPZIG
An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia - DE
Universitätsklinikum Leipzig AöR
UCCL - Universitäres Krebszentrum Leipzig
ITALY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission - IT
Institution: Information not provided - IT
ITALY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
ADMIRAL: A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation - IT
Institution: Information not provided - IT
NETHERLANDS
Groningen
GRONINGEN
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI >= 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged >=66 years - NL
UMCG - Universitair Medisch Centrum Groningen
Afdeling Hematologie
NETHERLANDS
Noord-Holland
AMSTERDAM
A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral selinexor (KPT-330) to standard induction chemotherapy in AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) in patients aged >= 66 years - NL
Amsterdam UMC, locatie VUmc
Afdeling Hematologie
NETHERLANDS
Zuid-Holland
LEIDEN
NETHERLANDS
Zuid-Holland
LEIDEN
Decitabine-cytarabine chemotherapy in elderly AML and high risk MDS patients (> 65 years) with high early mortality risk
LUMC - Leids Universitair Medisch Centrum
Afdeling Hematologie
SPAIN
Comunidad Valenciana
VALENCIA
Protocol for first line treatment adapted to risk of acute myeloblastic leukemia in patients less than or equal to 65 years
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAIN
Comunidad Valenciana
VALENCIA
IDHENTIFY: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation - ES
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAIN
Comunidad Valenciana
VALENCIA
QUIWI: A 2:1 randomized phase II trial to compare the efficacy and safety of standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in adult patients with newly diagnosed FLT3 wild-type AML - ES
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively [...] - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy -GB
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
QuANTUM-First: A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
LAMVYX: A phase II, multicentre, open label clinical trial to assess the efficacy and toxicity of induction and consolidation with CPX-351 for patients aged 60 to 75 years with secondary or high-risk acute myeloid leukemia - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
PEVOLAM: A Randomized Phase III, Multicentre, Open Label Clinical Trial Comparing Azacitidine Plus Pevonedistat Versus Azacitidine in Older/Unfit Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Chemotherapy - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A randomized (1:1), double-blind, multi-center, placebo controlled study evaluating intensive chemotherapy with or without Glasdegib (PF-04449913) or Azacitidine with or without Glasdegib in patients with previously untreated acute myeloid leukemia - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Randomized, Double-Blind, Placebo Controlled Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
HOVON 150 AML: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy Followed by Maintenance Therapy in Patients With Newly Diagnosed AML or MDS With Excess Blasts-2, With an IDH1 or IDH2 Mutation [...] - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
HOVON 156 AML: A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase I-II, Multicentre, Open Label Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine, Plus Venetoclax and Quizartinib in Newly Diagnosed Acute Myeloid Leukemia Patients Aged Equal or More Than 60 Years Old Ineligible for Standard Induction Chemotherapy - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
ENHANCE-2: A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician's Choice of Venetoclax in Combination with Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 Mutant Acute Myeloid Leukemia - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous of AB8939 in patients with Relapsed/Refractory Acute Myeloid Leukemia - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
ENHANCE-3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 as Monotherapy and in Combination With Azacitidine in Subjects With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1, Open-label, Dose-finding Study of CC-91633 (BMS-986397) in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
LAVA: A Phase 1 and 2a open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and antitumor activity of LAVA-051 in patients with relapsed or refractory CD1d-positive chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemia - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
Phase I, Open Label, Non-randomised, Non-comparative, Multi-center Study, Evaluating S65487, a Bcl-2 Inhibitor Intravenously Administered, in Patients With Relapse or Refractory Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1/2, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1, Open-label, Dose Finding Study of CC-95251 Alone and in Combination With Antineoplastic Agents in Subjects With Acute Myeloid Leukemia and Myelodysplastic Syndromes - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies - ES
Institution: Information not provided - ES
SPAIN
Madrid
MADRID
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial - ES
Hospital Universitario Fundación Jiménez Díaz
Servicio de Hematología y Hemoterapia
SWEDEN
Region Stockholm
ADDRESS: NOT PROVIDED - SE
AMoRE2017: International multicenter, open-label, phase 2 study to treat molecular relapse of pediatric acute myeloid leukemia with azacitidine - SE
Institution: Information not provided - SE
SWITZERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH
AMoRe2017: International multicenter, open-label, phase 2 study to treat molecular relapse of pediatric acute myeloid leukemia with Azacitidine - CH
Institution: Information not provided - CH
SWITZERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively [...] - CH
Institution: Information not provided - CH
SWITZERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH
An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia - CH
Institution: Information not provided - CH
SWITZERLAND
Suisse Romande
LAUSANNE
PTX3 Genetically Stratified Randomized Double-blinded Allocation Event-driven Clinical Trial for Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia
Centre Hospitalier Universitaire Vaudois CHUV
Service des maladies infectieuses
UNITED KINGDOM
Glasgow
GLASGOW
MyeChild 01: International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy - UK
Royal Hospital For Children, NHS Greater Glasgow & Clyde
Paediatrics (Ground Floor, Zone 1)
UNITED KINGDOM
Nottinghamshire
NOTTINGHAM
AML18: A Trial for Older Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome (Phase III) - UK
LAM Action Nottingham, Voluntary Action Centre
Department of Haematology
UNITED KINGDOM
Oxfordshire
OXFORD
A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies
Churchill Hospital
Department of Haematology
UNITED KINGDOM
South Glamorgan
CARDIFF
Phase 1b Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia-GB
University Hospital of Wales
Department of Haematology
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) - US
Institution: Information not provided - US
GERMANY
Sachsen
LEIPZIG
RELAZA2 (TUD-RELA02-048): Treatment of patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) with an impending hematological relapse with Azacitidin (Phase II)
Universitätsklinikum Leipzig AöR
Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie
AUSTRIA
STEIERMARK
GRAZ
HaploMUD: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial - AT
Medizinische Universität Graz
Klinische Abteilung für Hämatologie
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects > 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
ARMADA 2000: Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (>=60 years) with Relapsed/Refractory Acute Myeloid Leukemia (AML) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
Randomized Clinical Study of Haplo-Identical Donors Versus Unrelated Donors in Hematopoietic Stem Cell Transplant Patients With Acute Myeloid Leukemia - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
Clinical Phase II Trial to Describe the Safety and Efficacy of Treosulfan-based Conditioning Therapy Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Paediatric Patients With Haematological Malignancies - AT
St. Anna Kinderspital
Zentrum für Kinder- und Jugendheilkunde
BELGIUM
ANTWERPEN
ANTWERPEN
A Randomized, Double Blind Phase 1b/2 Study Of Pf 04449913 (Glasdegib) In Combination With Azacitidine In Patients With Previously Untreated Intermediate 2 Or High Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Blasts And Multi Lineage Dysplasia, Or Chronic Myelomonocytic Leukemia - BE
Ziekenhuis Netwerk Antwerpen (ZNA) - Campus Stuivenberg
Hematologie (Bloedziekten)
BELGIUM
ANTWERPEN
ANTWERPEN
HOVON 116 AML: A phase I/II feasibility study of panoninostat alone and the combination of panobinostat and decitabine prior to donor lymphocyte infusion in recipients of allogeneic stem cell transplantation with poor and very poor risk AML- BE
Ziekenhuis Netwerk Antwerpen (ZNA) - Campus Stuivenberg
Hematologie (Bloedziekten)
BELGIUM
ANTWERPEN
EDEGEM (ANTWERPEN)
Therapeutic efficacy of Wilms tumor gene (WT1) mRNA-electroporated autologous dendritic cell vaccination in patients with myeloid malignancies and multiple myeloma: a phase II trial
Antwerp University Hospital - UZA
Dienst hematologie en hemostase - UZA
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation.
Cliniques universitaires Saint-Luc - UCLouvain
Cliniques Universitaires Saint-Luc
BELGIUM
BRABANT WALLON
MONT-SAINT-GUIBERT
BELGIUM
LIEGE
LIEGE
Co-transplantation of Mesenchymal Stem Cells and HLA-mismatched Allogeneic Hematopoietic Cells After Nonmyeloablative Conditioning: a Phase II Randomized Double-blind Study
CHU de Liège - Site du Sart Tilman
Department of Hematology / Hématologie clinique - CHU de Liège
BELGIUM
NAMUR
YVOIR
Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation.
Cliniques Universitaires UCL de Mont-Godinne
CHU Dinant-Godinne UCL Namur
BELGIUM
OOST-VLAANDEREN
GENT
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Maintenance Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (and Young Adults Aged up to 21 Years) with FLT3-ITD mutations - BE
Kinderziekenhuis Prinses Elisabeth - UZ Gent
Pediatric Hematology-Oncology and Stem Cell Transplantation/Afdeling Hemato-oncologie en stamceltransplantatie kinderen
BELGIUM
VLAAMS BRABANT
LEUVEN
HOVON 132 AML/SAKK 30/13: Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score > 4.5) - BE
UZ Leuven - Campus Gasthuisberg
Department of Hematology
BELGIUM
VLAAMS BRABANT
LEUVEN
HOVON 102 AML / SAKK 30/09: Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS = 1.5) (phase II-III) - BE
UZ Leuven - Campus Gasthuisberg
Department of Hematology
BELGIUM
VLAAMS BRABANT
LEUVEN
A Phase I/IIa Trial to Evaluate the Safety and Efficacy of an Off-the-shelf ex Vivo Cultured Allogeneic NK Cell Preparation in Subjects With Acute Myeloid Leukemia in Complete Morphologic Remission With Measurable Residual Disease and no Strong Indication for Stem Cell Transplantation - BE
UZ Leuven - Campus Gasthuisberg
Department of Hematology
BELGIUM
VLAAMS BRABANT
LEUVEN
ISAKIDS: Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years of Age With Relapsed/Refractory B or T Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia in First or Second Relapse -BE
UZ Leuven - Campus Gasthuisberg
Kinderhematologie en -oncologie
FINLAND
Finland
HELSINKI
Two-stage, Two-arm, Open-Label Phase II Study of Venetoclax in Combination With Azacytidine in Acute Myeloid Leukemia Patients Selected Using Ex Vivo Drug Sensitivity Screening
HUS - Helsinki University Hospital
Comprehensive Cancer Center
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A phase I/II, open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of oral midostaurin and to evaluate the preliminary clinical and pharmacodynamic response in pediatric patients with relapsed or refractory acute leukemia - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Phase I, Multicenter, Open-label Study of Oral LGH447 in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome-FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are = 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
LYON
FRANCE
ILE-DE-FRANCE
LE CHESNAY
PONATINIB-AML : A Phase I-II Study to Assess Safety and Efficacy of the Combination of Ponatinib With High or Intermediate-Dose Cytarabine as Consolidation Therapy for Patients With Intermediate-Risk Cytogenetic FLT3-ITD AML iIn First Complete Remission
CH de Versailles - Hôpital André Mignot
Service d'Hématologie - Oncologie
FRANCE
ILE-DE-FRANCE
LE CHESNAY
MYLOfrance 4 (ALFA1401) : Gemtuzumab Ozogamicin + Cytarabine vs Idarubicin + Cytarabine in Elderly Patients With AML (Phase II-III)
CH de Versailles - Hôpital André Mignot
Service d'Hématologie - Oncologie
FRANCE
ILE-DE-FRANCE
PARIS
TBF-Cord : Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies (Phase II)
AP-HP.Sorbonne Université - Hôpital Saint-Antoine
Service d'hématologie
FRANCE
ILE-DE-FRANCE
PARIS
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Maintenance Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (and Young Adults Aged up to 21 Years) with FLT3-ITD mutations - FR
AP-HP.Sorbonne Université - Hôpital d'Enfants Armand-Trousseau
Service d'Hématologie - Oncologie pédiatrique
FRANCE
ILE-DE-FRANCE
PARIS
A Phase II Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q
GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis
Groupe Francophone des Myélodysplasies (GFM)
FRANCE
ILE-DE-FRANCE
PARIS
A phase II study of the efficacy and safety of lenalidomide combined to azacitidine in intermediate-2 or high risk MDS AND AML with del 5q (GFM-Aza-Rev-09)
GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis
Groupe Francophone des Myélodysplasies (GFM)
FRANCE
ILE-DE-FRANCE
PARIS
BERGAMO: A Phase II Study Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes Failing Standard of Care Therapy - FR
GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis
Service d'Hématologie seniors
FRANCE
ILE-DE-FRANCE
PARIS
Efficacy Study of Inecalcitol in Combination With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy (Phase II ) - FR
Hôpital Necker-Enfants Malades
Service d'Hématologie adulte
FRANCE
NOUVELLE AQUITAINE
PESSAC
EPAG 2015 : A phase II randomized placebo-controlled study to assess the impact on outcome of Eltrombopag administered to elderly patients with acute myeloid leukemia receiving induction chemotherapy
CHU de Bordeaux-GH Sud - Hôpital Haut-Lévêque
Service d'hématologie et thérapie cellulaire
FRANCE
OCCITANIE
TOULOUSE
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Maintenance Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (and Young Adults Aged up to 21 Years) with FLT3-ITD mutations - FR
CHU de Toulouse - Hôpital des Enfants
Hôpital des enfants
FRANCE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
Etude Phase I/II d'immunothérapie Par protéine recWT1-A10+AS01B après Greffe allogénique de Cellules Souches (Phase I-II) - FR
CLCC Institut Paoli Calmettes
Institut Paoli-Calmettes
FRANCE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
Prospective and Multicentre Evaluation of 3 Different Doses of IV Busulfan Associated With Fludarabine and Thymoglobuline in the Conditioning of Allogeneic Stem Cell Transplantation (SCT) From a Matched Related or Unrelated Donor in Patients With Poor Prognosis Myeloid Malignancies (Phase II) - FR
CLCC Institut Paoli Calmettes
Institut Paoli-Calmettes
GERMANY
Baden-Württemberg
FREIBURG
HaploMUD: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial - DE
Universitätsklinikum Freiburg
Klinik für Innere Medizin I - Hämatologie, Onkologie und Stammzelltransplantation
GERMANY
Baden-Württemberg
HEIDELBERG
INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Deutsches Krebsforschungszentrum
Klinische Kooperationseinheit Pädiatrische Onkologie
GERMANY
Baden-Württemberg
HEIDELBERG
TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib: A Multi-centre Matched Threshold Crossing Phase II Approach
Nationales Centrum für Tumorerkrankungen (NCT)
Nationales Centrum für Tumorerkrankungen (CCC) Heidelberg
GERMANY
Baden-Württemberg
TÜBINGEN
CD3/CD19 Haplo (E410/2007): Multicenter phase II study of Haploidentical Hematopoietic Cell Transplantation with CD3/CD19 depleted Grafts after a reduced intensity conditioning regimen for adult Patients with Acute Leukemia
Department für Innere Medizin - Medizinische Universitätsklinik Tübingen
Innere Medizin II - Onkologie, Hämatologie, Klinische Immunologie, Rheumatologie und Pulmologie
GERMANY
Baden-Württemberg
ULM
An open phase I/IIa trial to investigate the maximum tolerated dose, safety, pharmacokinetics, and efficacy of intravenous BI 6727 as monotherapy or in combination with subcutaneous Cytarabine in patients with Acute Myeloid Leukemia (AML) - DE
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
GERMANY
Baden-Württemberg
ULM
CLASSIC I: A Phase III Randomized, Double-blind, Controlled Study Comparing Clofarabine and Cytarabine Versus Cytarabine Alone in Adult Patients 55 Years and Older With Acute Myelogenous Leukemia (AML) Who Have Relapsed or Are Refractory After Receiving up to Two Prior Induction Regimens
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
GERMANY
Baden-Württemberg
ULM
AMLSG 11-08: Open-label, multicenter phase Ib/IIa study for the evaluation of Dasatinib following induction and consolidation therapy as well as in maintenance therapy in patients with newly diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
GERMANY
Baden-Württemberg
ULM
AMLSG 19-13: Dose Finding Run-in Phase I Followed by a Phase III, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of Crenolanib in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations - DE
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
GERMANY
Baden-Württemberg
ULM
A Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
GERMANY
Bayern
MÜNCHEN
TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib: A Multi-centre Matched Threshold Crossing Phase II Approach
Geschäftsstelle CCC München
CCC München - Comprehensive Cancer Center
GERMANY
Bayern
MÜNCHEN
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
LMU Klinikum der Universität München - Campus Großhadern
LMU Klinikum
GERMANY
Bayern
MÜNCHEN
AML-CG 2008: A Randomized, risk and age adapted comparison of the dose-dense regimen S-HAM (sequential high dose cytosine arabinoside and mitoxantrone) versus standard double induction for initial Chemotherapy of adult patients with Acute Myeloid Leukemia (Phase III)
LMU Klinikum der Universität München - Campus Großhadern
Medizinische Klinik und Poliklinik III
GERMANY
Bayern
REGENSBURG
INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Universitätsklinikum Regensburg
Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
CLBH589H2101 - A phase I/b, open-label, multicenter, dose-escalation study of oral panobinostat (LBH589) administered with 5-azacitidine (Vidaza®) in adult patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) - DE
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia -DE-
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
AZA-AML-004: A randomized, multicenter, open-label, Phase 2 study with a safety run-in part to evaluate safety, pharmacodynamics and efficacy of azacitidine compared to no anticancer treatment in children and young adults with acute myeloid leukemia in molecular relapse after first complete remission -DE-
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
A Phase 1/2 Study of Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Anthracycline-Based Induction Therapy -DE-
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are = 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy -DE-
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
PIVOT IO 020: Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies - DE
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
ISAKIDS: Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years of Age With Relapsed/Refractory B or T Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia in First or Second Relapse -DE
Institution: Information not provided - DE
GERMANY
Hamburg
HAMBURG
HaploMUD: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial - DE
UKE - Universitätsklinikum Hamburg-Eppendorf
Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation
GERMANY
Hessen
FRANKFURT AM MAIN
A Prospective Phase I/II Study to Investigate the Feasibility, Safety and Efficacy of IL-15 Activated Cytokine Induced Killer (CIK) Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After Allogeneic SCT - DE
Universitätsklinikum Frankfurt
Schwerpunkt Stammzelltransplantation und Immunologie
GERMANY
Hessen
FRANKFURT AM MAIN
PANOBEST: Phase I/II study with oral panobinostat maintenance therapy following allogeneic stem cell transplantation in patients with high risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Universitätsklinikum Frankfurt
Medizinische Klinik II - Hämatologie, Onkologie, Hämostaseologie, Rheumatologie, Infektiologie
GERMANY
Hessen
MARBURG
SORMAIN: A double-blind, placebo-controlled, randomised, multicentre phase II trial to assess the efficacy and safety of Sorafenib-maintenance therapy in Flt3-ITD positive Acute Myeloid Leukemia in complete haematological remission after allogenic stem cell transplantation
Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg
Klinik für Innere Medizin - Schwerpunkt Hämatologie, Onkologie und Immunologie
GERMANY
Niedersachsen
HANNOVER
HaploMUD: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial - DE
Medizinische Hochschule Hannover
Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation
GERMANY
Niedersachsen
HANNOVER
A Phase I/IIa Trial to Evaluate the Safety and Efficacy of an Off-the-shelf ex Vivo Cultured Allogeneic NK Cell Preparation in Subjects With Acute Myeloid Leukemia in Complete Morphologic Remission With Measurable Residual Disease and no Strong Indication for Stem Cell Transplantation - DE
Medizinische Hochschule Hannover
Medizinische Hochschule Hannover (MHH)
GERMANY
Nordrhein-Westfalen
DÜSSELDORF
Phase-II trial to assess the efficacy and toxicity of 5-Azacitidine in addition to standard donor lymphocyte for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplantation
Universitätsklinikum Düsseldorf
Klinik für Hämatologie, Onkologie und Klinische Immunologie
GERMANY
Nordrhein-Westfalen
DÜSSELDORF
AZALENA: Phase-II Trial to Assess the Efficacy and Safety of Lenalidomide in Addition to 5-Azacitidine and Donor Lymphocyte Infusions (DLI) for the Treatment of Patients With MDS, CMML or AML Who Relapse After Allogeneic Stem Cell Transplantation - DE
Universitätsklinikum Düsseldorf
Klinik für Hämatologie, Onkologie und Klinische Immunologie
GERMANY
Nordrhein-Westfalen
DÜSSELDORF
HaploMUD: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial - DE
Universitätsklinikum Düsseldorf
Klinik für Hämatologie, Onkologie und Klinische Immunologie
GERMANY
Nordrhein-Westfalen
DÜSSELDORF
IDH2-Post-Allo-Trial: Enasidenib as consolidation or salvage therapy for patients with IDH2 mutated AML or MDS following allogeneic blood stem cell transplantation
Universitätsklinikum Düsseldorf
Klinik für Hämatologie, Onkologie und Klinische Immunologie
GERMANY
Nordrhein-Westfalen
ESSEN
INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Universitätsklinikum Essen
Klinik für Kinderheilkunde III
GERMANY
Nordrhein-Westfalen
ESSEN
HaploMUD: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial - DE
Universitätsklinikum Essen
Klinik für Knochenmarktransplantation
GERMANY
Nordrhein-Westfalen
MÜNSTER
HaploMUD: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial - DE
Universitätsklinikum Münster
Medizinische Klinik und Poliklinik A
GERMANY
Sachsen
DRESDEN
Multicenter, Open-label, Adaptive Design Phase I Trial With Genetically Modified T-cells Carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in Combination With CD123 Target Module (TM123) for the Treatment of Patients With Hematologic and Lymphatic Malignancies Positive for CD123
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Nationales Centrum für Tumorerkrankungen Dresden
GERMANY
Sachsen
LEIPZIG
BERGAMO: A Phase II Study Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes Failing Standard of Care Therapy -DE
Universitätsklinikum Leipzig AöR
Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie
GERMANY
Sachsen-Anhalt
MAGDEBURG
CLDE225X2203: A Phase II multicenter, open label, randomized study to assess safety and efficacy of two different schedules of oral LDE225 in adult patients with relapsed / refractory or untreated elderly patients with Acute Leukemia - DE
Universitätsklinikum Magdeburg A.ö.R
Universitätsklinik für Hämatologie und Onkologie
GERMANY
Thüringen
JENA
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
Universitätsklinikum Jena
Klinik für Innere Medizin II - Abteilung Hämatologie und Internistische Onkologie
ITALY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR alfa-beta+ T cells in pediatric patients affected by hematological disorders
Institution: Information not provided - IT
ITALY
FRIULI VENEZIA GIULIA
UDINE
Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)
Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udine
Clinica Ematologica
ITALY
LAZIO
ROMA
Study protocol for acute myeloid leukemia in children and adolescent
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Oncoematologia
ITALY
LAZIO
ROMA
Clofarabine in combination with standard remission induction regimen (AraC and idarubicin) in patients 20-60 years old with previously untreated intermediate and bad risk acute myelogenous leukemia (AML)
Sapienza Università di Roma - DAI Neuroscienze e Salute Mentale
Dipartimento di Biotecnologie Cellulari ed Ematologia
ITALY
LIGURIA
GENOVA
Haploidentical Bone Marrow Transplantation With or Without NK Cell Infusion in Refractory/Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome: The BigEMINy Study
IRCCS Policlinico San Martino - Istituto Nazionale per la Ricerca sul Cancro
Divisione di Ematologia
ITALY
LOMBARDIA
BRESCIA
Phase II Study on Venetoclax (VEN) Plus Decitabine (DEC) (VEN-DEC) for Elderly (60 Years to 75 Years) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation (Allo-SCT)
ASST Spedali Civili di Brescia
Centro Trapianto Midollo Adulti
ITALY
LOMBARDIA
MILANO
Multicenter Phase II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts After a Reduced Intensity Conditioning Regimen for Adult Patients With Acute Leukemia
IRCCS Ospedale San Raffaele
Unità di Ematologia e Trapianto di Midollo Osseo
ITALY
LOMBARDIA
MILANO
A Phase I-IIa Trial to Assess the Safety and Antitumor Activity of Autologous CD44v6 CAR T-cells in Acute Myeloid Leukemia and Multiple Myeloma Expressing CD44v6
IRCCS Ospedale San Raffaele
Unità di Ematologia e Trapianto di Midollo Osseo
ITALY
LOMBARDIA
MONZA
ISAKIDS - Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years of Age With Relapsed/Refractory B or T Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia in First or Second Relapse - IT
ASST Monza - Ospedale San Gerardo
Clinica Pediatrica
NETHERLANDS
Gelderland
NIJMEGEN
Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial)
Radboudumc - Radboud universitair medisch centrum
Afdeling Hematologie
NETHERLANDS
Utrecht
UTRECHT
A phase I study to investigate the safety of TEG001 cell suspension for infusion in patients with relapsed/refractory Acute Myeloid Leukemia, high-risk Myelodysplastic Syndrome (IPSS-R score >4,5) or Multiple Myeloma
UMC Utrecht - Universitair Medisch Centrum Utrecht
Afdeling Hematologie
NETHERLANDS
Zuid-Holland
LEIDEN
Clofarabine in combination with a standard remission induction regimen (AraC and idarubicin) in patients 18-60 years old with previously untreated intermediate and bad risk acute myelogenous leukemia (AML) or high risk myelodysplasia (MDS): a phase I-II study of the EORTC-LG and GIMEMA (AML-14A trial)
LUMC - Leids Universitair Medisch Centrum
Afdeling Hematologie
NETHERLANDS
Zuid-Holland
LEIDEN
Prophylactic infusion of CD4 positive donor lymphocytes early after T-cell depleted allogeneic stem cell transplantation in patients with an unrelated donor (phase II)
LUMC - Leids Universitair Medisch Centrum
Afdeling Hematologie
NETHERLANDS
Zuid-Holland
ROTTERDAM
COMPARE 60/80 HBR: Comparison of the Supraflex Cruz 60 Micron Stent Strut Versus the Ultimaster Tansei 80 Micron Stent Strut in High Bleeding Risk PCI Population
Maasstad Ziekenhuis
Polikliniek Cardiologie
NORWAY
Vestlandet
BERGEN
A Phase II Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia - NO -
Haukeland University Hospital
POLAND
Lodz
LODZ
Evaluation of the Efficacy of Induction-consolidation Treatment Using a Double Induction in Patients With AML <60 Years Old, Depending on the Percentage of Blasts in the 14 Day, Residual Disease and Leukemic Hematopoietic Cells
Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi
Oddzial Hematologii
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Maintenance Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years [...] with FLT3-ITD mutations - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects >= 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML) - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
PANTHER: A Phase 3, Randomized, Controlled, Open-Label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
STIMULUS-AML1: A phase II multi-center, single arm, safety and efficacy study of MBG453 in combination with azacitidine and venetoclax for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase I/II Study of SEL24 in Patients with Acute Myeloid Leukemia - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A single arm, open-label, phase 4 study evaluating qt interval, pharmacokinetics, and safety of gemtuzumab ozogamicin (MYLOTARG) as a single-agent regimen in patients with relapsed or refractory CD33-positive acute myeloid leukemia - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
FLAG-QUIDA: A multicenter, prospective, non-randomized, Phase I-II trial to assess the efficacy and safety of the combination of oral quizartinib and the FLAG-IDA chemotherapy regimen in first relapsed/refractory acute myeloid leukemia (R/R AML) patients - ES
Institution: Information not provided - ES
SWEDEN
Region Stockholm
ADDRESS: NOT PROVIDED - SE
Study to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score > 4.5) - SE
Institution: Information not provided - SE
SWEDEN
Region Stockholm
ADDRESS: NOT PROVIDED - SE
HOVON 102 AML / SAKK 30/09: Study to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS = 1.5) - SE
Institution: Information not provided - SE
SWITZERLAND
Suisse Alémanique
BASEL
SWITZERLAND
Suisse Alémanique
ZÜRICH
A Phase I/IIa Trial to Evaluate the Safety and Efficacy of an Off-the-shelf ex Vivo Cultured Allogeneic NK Cell Preparation in Subjects With Acute Myeloid Leukemia in Complete Morphologic Remission With Measurable Residual Disease and no Strong Indication for Stem Cell Transplantation - CH
Universitätspital Zürich
University Hospital Zurich
SWITZERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase I/II, Open-label, Dose-Escalating Study With a Proof of Concept Cohort to Evaluate the Safety, Tolerability and Efficacy of ARGX-110 in Combination With Azacytidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
Institution: Information not provided - CH
UNITED KINGDOM
Essex
HARLOW
ASPIRE: A three-part, phase II study of Eltrombopag in thrombocytopenic subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: open-label, part 2: randomized, double-blind, part 3: extension) - DE
GlaxoSmithKline Research & Development Ltd.
GlaxoSmithKline Research & Development Limited
UNITED KINGDOM
Greater London
LONDON
CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders-GB
GOSH NHS Foundatin Trust
Great Ormond Street Hospital
UNITED KINGDOM
Greater London
LONDON
UK Haplo v1.0: A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies
Guy's Hospital
Department of Haematology
UNITED KINGDOM
Greater London
UXBRIDGE
UNITED KINGDOM
West Midlands
BIRMINGHAM
UNITED KINGDOM
West Midlands
BIRMINGHAM
UNITED KINGDOM
West Midlands
BIRMINGHAM
PARC: Phase I/II Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) in Relapsed/Refractory Cancers of Children and Young Adults -GB
University of Birmingham
University of Birmingham HQ
UNITED STATES
Alabama
BIRMINGHAM
A Randomized, Double-blind Phase 1b/2 Study Of Pf-04449913 (Glasdegib) In Combination With Azacitidine In Patients With Previously Untreated Intermediate-2 Or High-risk Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Blasts And Multi-lineage Dysplasia, Or Chronic Myelomonocytic Leukemia - US
University of Alabama at Birmingham
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Maintenance Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (and Young Adults Aged up to 21 Years) with FLT3-ITD mutations - FR
Institution: Information not provided - US
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
ITALY
LAZIO
ROMA
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Oncoematologia
Multinational clinical trial(s)
FRANCE
ILE-DE-FRANCE
PARIS
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
AMoRE2017: International multicenter, open-label, phase 2 study to treat molecular relapse of pediatric acute myeloid leukemia with azacitidine
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
SAMBA-trial: Single Agent JNJ-56022473 in MDS and AML Patients Failing Hypomethylating Agent Based Therapy
Institution: Information not provided - DE
NETHERLANDS
Groningen
GRONINGEN
HO155: A Randomized Phase II Multicenter Study to Assess the Tolerability and Efficacy of the Addition of Midostaurin to 10-day Decitabine Treatment in Unfit Adult Acute Myeloid Leukemia and High Risk Myelodysplasia Patients
UMCG - Universitair Medisch Centrum Groningen
NETHERLANDS
Noord-Holland
AMSTERDAM
SAIL: An Investigator-Initiated Study To Evaluate Ara-C and Idarubicin in Combination with the Selective Inhibitor Of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Relapsed Or Refractory AML
GSO Global Clinical Research B.V.
SWITZERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase IB/II Multi-Arm Study With Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Institution: Information not provided - CH
SWITZERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Institution: Information not provided - CH
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK
SEAMLESS: A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Institution: Information not provided - UK
UNITED STATES
California
PLEASANTON
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia
Astex Pharmaceuticals, Inc
UNITED STATES
California
PLEASANTON
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Guadecitabine Clinical Studies (Phase II)
Astex Pharmaceuticals, Inc
UNITED STATES
California
SAN DIEGO
Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With FLT3-ITD Activating Mutations (coordination)
Ambit Biosciences Corporation
UNITED STATES
Massachusetts
BOSTON
A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)
Dana-Farber Cancer Institute Boston
Dana-Farber Cancer Institute
UNITED STATES
New Jersey
EDISON
QuANTUM First: A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Daiichi Sankyo Pharma Development
UNITED STATES
New Jersey
RARITAN
An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia
Janssen Research & Development, LLC
Janssen Research & Development, LLC.
UNITED STATES
New York
NEW YORK
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
Efficacy Study of Inecalcitol in Combination with Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
AUSTRALIA
Victoria
RICHMOND
Phase III Clinical Study of Allogeneic Stem CellTransplantation with Reduced Conditioning (RICT)versus Best Standard of Care in Acute Myeloid Leukemia(AML) in First Complete Remission
Australasian Leukaemia & Lymphoma Group (ALLG)
GERMANY
Hamburg
HAMBURG
HaploMUD: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial
UKE - Universitätsklinikum Hamburg-Eppendorf
Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation
GERMANY
Sachsen
LEIPZIG
BERGAMO: A Phase II Study Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes Failing Standard of Care Therapy
Universitätsklinikum Leipzig AöR
Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie
NORWAY
Østlandet
OSLO
SWEDEN
Region Stockholm
ADDRESS: NOT PROVIDED - SE
SPARK-AML1: A Randomised, Open-label, Multi-centre, 2-stage, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC) in Comparison With LDAC Alone in Patients Aged > 60 With Newly Diagnosed Acute Myeloid Leukaemia (AML) (Phase II) (coordination)
Institution: Information not provided - SE
UNITED KINGDOM
West Midlands
BIRMINGHAM
UNITED STATES
Massachusetts
CAMBRIDGE
AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Agios Pharmaceuticals, Inc.
UNITED STATES
New Jersey
EDISON
UNITED STATES
New Jersey
RARITAN
Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) (Phase III) (coordination)
Johnson & Johnson
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
UNITED STATES
Texas
HOUSTON
CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders
Bellicum Pharmaceuticals, Inc.
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Institution: Information not provided - US
SPAIN
Madrid
COLMENAR VIEJO